
    
      The study was conducted as an open label, balanced, randomised, two-treatment, two-period,
      two-sequence, single-dose, crossover , bioequivalence study on Amlodipine besylate
      formulations comparing Amlodipine 10mg tablets of Ranbaxy Laboratories with (NorvascÂ®, Pfizer
      Inc USA, in healthy, adult, human, subjects under fed conditions

      Enrolled and randomized: 40 each treatment) Drop-outs (withdrew from study): 1 Withdrawals
      (was dropped from study): 4 Completed: 36
    
  